Professor Rajendra R Aparasu the pharmaceutical department chair at the University of Houston has been selected for the Fulbright Specialist Roster, for his achievements in the field of pharmacy. The Indian-origin Professor hailing from Mahbubnagar district, Telangana in India is the first professor at the University of Houston selected for the Fulbright Specialist Programme.
The Department of State's Bureau of Educational and Cultural Affairs is funding the Fulbright programme, that aims at helping the US faculty share their academic expertise and develop links with non-US institutions on curriculum, assessment, faculty development and research training. The Fulbright programme funded by the Department of State’s Bureau of Educational and Cultural Affairs, promotes international engagement of academic scholarships.
On his selection, the Professor said that there are very few Fulbright specialists in pharmacy and he is honored to be selected for the Roster. "There are very few Fulbright specialists in pharmacy; I am really honored to be selected for Fulbright Specialist Roster," said Aparasu, whose five-year term ends in 2021. He also said that this is a great opportunity to offer his expertise in developing professional and graduate pharmacy programmes that involve pharmaceutical health outcomes and policy.
He completed his Bachelor of Pharmacy (BPharm) from Kakatiya University, and Master of Pharmacy (MPharm), from Jadavpur University in India. He obtained his PhD in Pharmacy Administration, University of Louisiana, Monroe, LA before joining the University of Texas in 2006, after serving at the South Dakota State University faculty for over a decade. His primary areas of expertise include geriatrics, pharmacoepidemiology, psychopharmacology and evidence-based medicine.
He has been recognised by his peers with the Fellow of the American Pharmacists Association and holds editorial board appointments on 6 peer-review journals. He has also authored and co-authored over 100 journal articles, and has been recognized as an "exceptional" reviewer by the peer-review journals.